title: Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women.
abstract: The aim of this study was to determine the respective contribution of abdominal visceral adipose tissue (AT) accumulation and insulin resistance (IR) to the determination of a comprehensive cardiovascular metabolic risk profile in 108 postmenopausal women not receiving hormone therapy. Insulin sensitivity (M/I) was determined by a hyperinsulinemic-euglycemic clamp, and visceral AT area was measured by computed tomography. Median values of visceral AT (133.9 cm(2)) and insulin sensitivity (0.010189 mg . kg(-1) . min(-1) . pmol(-1)) were used to form four subgroups: 1) low visceral AT-low IR (n = 35), 2) low visceral AT-high IR (n = 19), 3) high visceral AT-low IR (n = 19), and 4) high visceral AT-high IR (n = 35). Women with isolated IR (low visceral AT and high IR) were characterized by significantly higher fasting and 2-h glycemia and higher fibrinogen, triglyceride, and VLDL-apolipoprotein (apo)B concentrations than women with low visceral AT and low IR (P < 0.05). The plasma lipid-lipoprotein profile and inflammatory markers were not significantly different between women with high visceral AT and low IR and women with low visceral AT and low IR. Women with high visceral AT and high IR had higher fasting and 2-h glycemia, triglyceride, and VLDL-apoB levels; lower apoAI and HDL(2) cholesterol levels; as well as higher C-reactive protein and interleukin-6 concentrations than women with low visceral AT and low IR (P < 0.05). In addition, 15 of the 35 women (42.9%) in the high visceral AT and high IR group were newly diagnosed with type 2 diabetes, whereas no women were diagnosed with type 2 diabetes in the group of women with low visceral AT and low IR. These results show that although the presence of high IR in its isolated form is associated with some metabolic alterations, it is the combination of both high visceral AT and high IR that is the most detrimental for the metabolic health in postmenopausal women.
authors.affiliation: Institute of Nutraceuticals and Functional Foods, 2440 Hochelaga Blvd., Laval University, Québec (Québec), Canada, G1K 7P4.
authors.forename: Marie-Eve
authors.initials: ME
authors.lastname: Piché
authors.forename: S John
authors.initials: SJ
authors.lastname: Weisnagel
authors.forename: Louise
authors.initials: L
authors.lastname: Corneau
authors.forename: André
authors.initials: A
authors.lastname: Nadeau
authors.forename: Jean
authors.initials: J
authors.lastname: Bergeron
authors.forename: Simone
authors.initials: S
authors.lastname: Lemieux
mesh_terms: D000273:Adipose Tissue / Q000502:physiology*; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D015850:Interleukin-6 / Q000097:blood; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000503:physiopathology*; D017698:Postmenopause / Q000097:blood / Q000502:physiology*; D012306:Risk
chemical_list: D015850:Interleukin-6; D008055:Lipids; D005340:Fibrinogen; D002097:C-Reactive Protein